908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market

Key Points

• 908 Devices is refocusing on handheld chemical and drug detection after divesting its bioprocessing and biopharma business, targeting public-safety, law-enforcement and defense markets.
• The company is expanding its portfolio with NIRLab, a cloud-connected device that can identify roughly 400 drugs in seconds, while its MX908 and VipIR systems address synthetic opioids, chemical threats and hazardous materials.
• 908 Devices cited defense-program opportunities, recurring grant funding and substantial manufacturing capacity, supported by more than $100 million in cash and several years of financial runway for growth and acquisitions.

908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.

Chief Executive Officer and co-founder Kevin Knopp said the company was founded in 2012 to bring laboratory-grade mass spectrometry into portable, battery-powered devices that can provide answers at the point of need. While the company expanded into life sciences around its 2020 IPO, it has since returned to its original focus on chemical detection, including synthetic opioids, toxic industrial chemicals and chemical threats.

“We’re fully focused on the category of defining handheld detection for these public health, safety, and defense markets,” Knopp said.

Field Results Intended to Reduce Lab Delays

Knopp said law-enforcement forensic laboratories can face backlogs of six to nine months, delaying drug-case processing. He said 908 Devices’ products can provide presumptive results in roughly 30 seconds in certain applications, allowing agencies to use results for probable cause or faster case processing where approved by state authorities.

The company works with law-enforcement, corrections, fire and hazardous-materials customers globally. Knopp cited hazmat situations involving leaking tanks as an example where rapid field identification and quantification of an unknown gas can help agencies assess risks to personnel and communities.

The company’s product line spans several technologies and use cases:

• MX908: The company’s flagship mass spectrometry device, with approximately 3,000 units in the field. It is used for detecting synthetic opioids, chemical weapons, nontraditional chemical agents and other threats.
• VipIR: A bulk chemical identification product combining FTIR and Raman technologies with algorithms. Knopp said it can measure 38,000 analytes and is aimed at customs agencies, ports of entry and hazmat teams.
• NIRLab: A recently acquired handheld bulk-identification device designed for routine police drug screening. Users can touch the device to pills or substances, and it can identify about 400 drug substances in seconds, according to Knopp.

NIRLab Acquisition Adds European Reach

Knopp said NIRLab originated at the University of Lausanne in Switzerland and has been validated through scientific publications and use in Europe. He said the acquisition gives 908 Devices an opportunity to bring the product into the U.S. market through its existing public-safety sales organization.

The company estimates the directly addressed opportunity for NIRLab at approximately $200 million within a broader $1.5 billion to $2 billion market for detection equipment. Knopp also pointed to regulatory changes in Colorado and roughly seven other states affecting the use of colorimetric drug-test kits for arrest decisions.

He said the cloud-connected, subscription-based NIRLab system may help agencies maintain audit trails and chain-of-custody documentation while providing an alternative to wet-chemistry kits, which can involve expiration concerns, user interpretation and the potential consumption of a sample.

Cloud connectivity is also a longer-term focus across the company’s portfolio. Knopp said connected systems can enable customers to monitor device activity, manage fleets and identify substance trends within their own networks. The company is working to connect all of its devices to a common ecosystem, including a next-generation version of the MX908 anticipated by the end of the year.

Defense Programs and Funding Environment

Knopp discussed the company’s involvement in the Army’s AVCAD program, which addresses aerosol and vapor detection requirements. 908 Devices has worked with Smiths Detection on the program and recently completed a low-rate initial production contract by delivering approximately 150 component sets to Smiths for a government testing and preparation phase.

The government is evaluating whether to continue with a custom-developed solution, use the company’s commercial MX908 product, or pursue a hybrid approach, Knopp said. He added that the detection technology in the AVCAD development is the same technology used in the commercial MX908.

Knopp also said grant funding remains important for state and local customers. He cited recent funding for High Intensity Drug Trafficking Area programs, the Department of Justice’s COPS program and Urban Area Security Initiative grants, saying the funding environment should support customers over multiple years.

Manufacturing Capacity and Financial Position

Chief Financial Officer Joe Griffith said 908 Devices manufactures its products at a roughly 40,000-square-foot facility in Danbury, Connecticut, where it consolidated operations during 2025. The company produced about 700 devices in 2025, while the site has capacity to manufacture thousands of devices, he said.

Griffith said U.S. list prices range from $10,000 for NIRLab to more than $100,000 for VipIR. The MX908 has a list price of about $75,000, while larger military deployments can involve 50 to more than 100 devices, according to Griffith.

As of June 30, the company had more than $100 million in cash, Griffith said. He added that adjusted EBITDA burn was in the mid-single-digit-million range during 2026, which he said provides multiple years of runway for organic growth, international expansion, product launches and potential acquisitions.

About 908 Devices (NASDAQ:MASS)

908 Devices Inc NASDAQ: MASS is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company's core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices' portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source